Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrico Franceschi

Showing results (71-80 of 162) with videos related to

Pageof 17
Sort By:
Frontiers in Oncology|April 16, 2026
Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical reviewGiovanni Dima, Vincenzo Di Nunno, Marta Aprile, et al.
Oncotarget|July 14, 2016
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastomaSalveena Schiffgens, Ludwig Wilkens, Alba A Brandes, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2021
Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational studyAlicia Tosoni, Lidia Gatto, Enrico Franceschi, et al.
Virchows Archiv : an International Journal of Pathology|October 28, 2008
Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20Gianluca Marucci, Luca Morandi, Elisabetta Magrini, et al.
Cancer|June 11, 2009
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation statusAlba A Brandes, Enrico Franceschi, Alicia Tosoni, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2026
Association of proton pump inhibitor use with outcome of patients with recurrent glioblastomaEmilie Le Rhun, Debaleena Sain, Martin van den Bent, et al.
Biomedicines|January 8, 2025
Targeting Mitochondria in Glioma: New Hopes for a CureLidia Gatto, Vincenzo Di Nunno, Anna Ghelardini, et al.
Neuroimage. Clinical|January 6, 2026
Individualized functionnectome for the statistical assessment of white matter circuits underlying task-fMRI activations in glioma patientsGiovanni Sighinolfi, Alexander Leemans, David Neil Manners, et al.
Journal of Neuro-Oncology|April 20, 2018
Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?Enrico Franceschi, Giuseppe Lamberti, Alexandro Paccapelo, et al.
Clinical Case Reports|August 30, 2021
Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature reviewLidia Gatto, Enrico Franceschi, Alicia Tosoni, et al.
Pageof 17

Showing results (71-80 of 162) with videos related to

Sort By:
Pageof 17
Frontiers in Oncology|April 16, 2026
Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical reviewGiovanni Dima, Vincenzo Di Nunno, Marta Aprile, et al.
Oncotarget|July 14, 2016
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastomaSalveena Schiffgens, Ludwig Wilkens, Alba A Brandes, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2021
Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational studyAlicia Tosoni, Lidia Gatto, Enrico Franceschi, et al.
Virchows Archiv : an International Journal of Pathology|October 28, 2008
Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20Gianluca Marucci, Luca Morandi, Elisabetta Magrini, et al.
Cancer|June 11, 2009
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation statusAlba A Brandes, Enrico Franceschi, Alicia Tosoni, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2026
Association of proton pump inhibitor use with outcome of patients with recurrent glioblastomaEmilie Le Rhun, Debaleena Sain, Martin van den Bent, et al.
Biomedicines|January 8, 2025
Targeting Mitochondria in Glioma: New Hopes for a CureLidia Gatto, Vincenzo Di Nunno, Anna Ghelardini, et al.
Neuroimage. Clinical|January 6, 2026
Individualized functionnectome for the statistical assessment of white matter circuits underlying task-fMRI activations in glioma patientsGiovanni Sighinolfi, Alexander Leemans, David Neil Manners, et al.
Journal of Neuro-Oncology|April 20, 2018
Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?Enrico Franceschi, Giuseppe Lamberti, Alexandro Paccapelo, et al.
Clinical Case Reports|August 30, 2021
Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature reviewLidia Gatto, Enrico Franceschi, Alicia Tosoni, et al.
Pageof 17